CytoDyn (CYDY) Accounts Payables (2011 - 2026)
CytoDyn's (CYDY) quarterly Accounts Payables came in at $13.5 million in Q1 2026, down 10.9% YoY from $15.1 million in Q1 2025, and down 5.38% on a QoQ basis from $14.2 million in Q4 2025.
CytoDyn (CYDY) Accounts Payables (2011 - 2026) Analysis & Trends
CytoDyn (CYDY) has 16 years of Accounts Payables data on file, last reported at $13.5 million in Q1 2026.
- Quarterly Accounts Payables fell 10.9% year-over-year to $13.5 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $13.5 million (down 10.9% YoY) and the FY2025 annual result came in at $14.7 million, down 50.3% from the prior year.
- Accounts Payables fell to $13.5 million in Q1 2026, from $14.2 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $69.0 million in Q3 2022 to a low of $13.5 million in Q1 2026.
- A 5-year average of $41.7 million and a median of $62.1 million in 2024 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables rose 15.86% — and 2024, when it plunged 77.44%.
- Tracing CYDY's Accounts Payables over 5 years: stood at $67.2 million in 2022, then declined by 7.25% to $62.3 million in 2023, then tumbled by 77.15% to $14.2 million in 2024, then increased by 0.01% to $14.2 million in 2025, then fell by 5.38% to $13.5 million in 2026.
- The last three Accounts Payables figures came in at $13.5 million (Q1 2026), $14.2 million (Q4 2025), and $14.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - | 13.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 13.48 Mn |
| Nov 30, 2025 | 14.25 Mn |
| Aug 31, 2025 | 14.18 Mn |
| May 31, 2025 | 14.69 Mn |
| Feb 28, 2025 | 15.13 Mn |
| Nov 30, 2024 | 14.24 Mn |
| Aug 31, 2024 | 14.16 Mn |
| May 31, 2024 | 29.56 Mn |
| Feb 29, 2024 | 62.10 Mn |
| Nov 30, 2023 | 62.33 Mn |
| Aug 31, 2023 | 62.77 Mn |
| May 31, 2023 | 62.73 Mn |
| Feb 28, 2023 | 62.67 Mn |
| Nov 30, 2022 | 67.20 Mn |
| Aug 31, 2022 | 69.00 Mn |
| May 31, 2022 | 67.97 Mn |
| Feb 28, 2022 | 62.40 Mn |
| Nov 30, 2021 | 58.00 Mn |
| Aug 31, 2021 | 65.90 Mn |
| May 31, 2021 | 65.90 Mn |